Stryker Corporation (NYSE:SYK) Shares Purchased by Saturna Capital Corp

Saturna Capital Corp boosted its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 0.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 314,441 shares of the medical technology company's stock after purchasing an additional 1,000 shares during the quarter. Stryker makes up approximately 1.8% of Saturna Capital Corp's holdings, making the stock its 23rd biggest position. Saturna Capital Corp owned 0.08% of Stryker worth $117,051,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SYK. Norges Bank bought a new position in Stryker in the 4th quarter worth approximately $1,710,744,000. GAMMA Investing LLC boosted its position in shares of Stryker by 43,226.8% during the 1st quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company's stock valued at $772,390,000 after acquiring an additional 2,070,133 shares during the last quarter. FMR LLC boosted its position in shares of Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after acquiring an additional 727,850 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Stryker during the 4th quarter valued at approximately $154,140,000. Finally, Northern Trust Corp boosted its position in shares of Stryker by 13.2% during the 4th quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock valued at $1,298,426,000 after acquiring an additional 420,153 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Down 0.0%

Shares of NYSE:SYK traded down $0.06 on Friday, hitting $388.84. 1,716,294 shares of the company's stock were exchanged, compared to its average volume of 1,355,776. Stryker Corporation has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a market capitalization of $148.42 billion, a price-to-earnings ratio of 52.55, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91. The business's 50 day simple moving average is $385.51 and its two-hundred day simple moving average is $377.73. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period last year, the company earned $2.50 earnings per share. Analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Analyst Ratings Changes

SYK has been the subject of a number of research reports. BTIG Research reiterated a "buy" rating on shares of Stryker in a research report on Monday. Needham & Company LLC reiterated a "buy" rating and set a $442.00 target price on shares of Stryker in a research report on Friday, March 21st. Roth Mkm increased their target price on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Citigroup reiterated a "buy" rating and set a $455.00 target price (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, Evercore ISI increased their target price on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $428.55.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director owned 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.